Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1297184 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $20.38Day −0.97%Mkt cap $899MP/E (FY) 10.0×1Y −4.5%Off 52W high −34.8%Vol (1Y) 55.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,040 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesUNDEMANDING · −3.7% growth |
| Short interest9.5% of sh out |
| Days to cover11.2d |
| 13F net flow (QoQ)−3.61% |
| Top-10 13F concentration54.6% |
| Next report (est.)2026-08-06 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)10.0× |
| Sales (TTM)$720.5M |
| Earnings (TTM)$79.2M |
| Net margin13.6% |
| ROIC9.9% |
| EPS growth 3Y5.3% |
| YTD−23.9% |
| 1Y−4.5% |
| 3Y−66.4% |
| 5Y−2.7% |
| 10Y+25.1% |
| Since incept. (ann.)+7.2% |
Total return through 2026-07-30 · series begins 2014-06-25. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)55.5% |
| Ann. volatility (3Y)46.6% |
| Sharpe (1Y)0.18 |
| Sharpe (3Y)−0.55 |
| Max drawdown (1Y)−45.2% |
| Max drawdown (3Y)−74.0% |
| Beta (3Y vs SPY)0.98 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 5.4M | $106M | 11.95% | −0.7% |
| DIMENSIONAL FUND ADVISORS LP | 2.0M | $40M | 4.47% | +12.7% |
| STATE STREET CORP | 1.6M | $31M | 3.54% | +4.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $30M | 3.40% | new |
| TD Asset Management Inc | 1.5M | $30M | 3.40% | −21.5% |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1.4M | $27M | 3.08% | −50.0% |
| MARSHALL WACE, LLP | 1.0M | $20M | 2.26% | −17.1% |
| AMERICAN CENTURY COMPANIES INC | 1.0M | $20M | 2.24% | +52.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.14 | −72.5% | $171.2M | +0.4% |
| 2025-12-31 | 2026-02-26 | — | — | $183.1M | −1.8% |
| 2025-09-30 | 2025-11-06 | $0.37 | −52.6% | $191.8M | +0.3% |
| 2025-06-30 | 2025-08-07 | $0.64 | −12.3% | $174.4M | −4.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Pharmaceutical Products 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Sales growth 3Y13.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
